11 Novel agonists of benzodiazepine receptors: design, synthesis, binding assay and pharmacological evaluation of 1,2,4-triazolo[1,5-a]pyrimidinone and 3-amino-1,2,4-triazole derivatives.

12 Chemokine receptor antagonists enhance the antinociceptive activity of oxycodone and meperidine on incisional pain in rats.

13 Prothrombin Complex Concentrates are Superior to Fresh Frozen Plasma for Emergency Reversal of Vitamin K Antagonists: A Meta-Analysis in 2606 Subjects.

14 Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.

15 Long-Term Vitamin K Antagonists and Cancer Risk: A Systematic Review and Meta-Analysis.

16 Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in secondary stroke and systemic embolism prevention.

17 Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.

18 Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation – a meta-analysis of more than 17000 patients

19 Corrigendum to “Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis” [Arch. Gerontol. Geriatr. 81 (March–April)(2019)209–214](S0167494318302450)(10.1016/j.archger.2018.12.013)

20 Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation: a Systematic Review and Meta-analysis

21 Net clinical benefit analysis of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: Protocol for a systematic review and meta-analysis

22 Low-intensity anti-coagulation using Vitamin K antagonists and Factor X activity: A validation analysis of the MAGENTUM-1 study

23 Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis

24 Efficacy and safety of reduced-dose non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation: A meta-analysis of randomized controlled trials

25 Efficacy and safety of prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage: a systematic review and meta-analysis

26 Outcomes of intraparenchymal hemorrhage after direct oral anticoagulant or vitamin K antagonist therapy: A systematic review and meta-analysis

27 Use of vitamin K antagonists and risk of prostate cancer: Meta–analysis and nationwide case–control study

28 Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis

29 Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis

30 Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis

31 A Systematic Review and Meta-analysis of the Association Between Vitamin K Antagonist Use and Fracture

32 Comment on “Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis”

33 Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies

34 Efficacy and Safety of the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Ischemic Heart Disease: A Meta-Analysis of Phase III Randomized Trials

35 Decreased risk of renal impairment in atrial fibrillation patients receiving non-vitamin K antagonist oral anticoagulants: A pooled analysis of randomized controlled trials and real-world studies

36 DOACs vs Vitamin K Antagonists: a Comparison of Phase III Clinical Trials and a Prescriber Support Tool

37 Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine

38 Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine

39 Glucocorticoid Receptor Antagonist Administration Prevents Adrenal Gland Atrophy in an ACTH-Independent Cushing’s Syndrome Rat Model

40 Health Related Quality of Life in Individuals Transferred from a Needle Exchange Program and Starting Opioid Agonist Treatment

41 Petroleum degradation by Pseudomonas sp. ZS1 is impeded in the presence of antagonist Alcaligenes sp. CT10

42 The alpha-2 receptor agonist dexmedetomidine attenuates vancomycin‑induced acute kidney injury.

43 Patient Reported Outcomes Following Initiation of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes in a Specialist Endocrinology Practice of the LMC Diabetes Registry: The PROGRESS-Diabetes Study.

44 The possible synergistic action of sex hormones and glucagon-like peptide-1 (GLP-1) agonists on body mass decline in patients with type 2 diabetes mellitus.

45 Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin

46 The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials

47 GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective

48 Evidence-based comparison of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors.

49 Effect of beta -adrenergic agonist and resistance training on maximal oxygen uptake and muscle oxidative enzymes in men.

50 Evaluation of the effects of commonly used α-adrenergic receptor agonists alone and in combination with butorphanol tartrate on objective measurements of lameness in horses.

51 Suppressive effects of type I angiotensin receptor antagonists, candesartan and irbesartan on allergic asthma

52 Pharmacogenetic Aspects of the Interaction of AT1 Receptor Antagonists With ATP-Binding Cassette Transporter ABCG2

53 The effects of angiotensin II receptor antagonist (candesartan) on rat renal vascular resistance

54 Internalization of Constitutively Active N111G Mutant of AT1 Receptor Induced by Angiotensin II–Receptor Antagonists Candesartan, Losartan, and Telmisartan: Comparison With Valsartan

55 Isolation and Characterization of Plant Growth Promoting Antagonistic Bacteria from Cotton and Sugarcane Plants for Suppression of Species.

56 Procesos de significación mediados por una plataforma de aprendizaje colaborativo desde los protagonistas

57 Sigma-1 receptor antagonist, PD144418, selectively reduces female motivation for food during negative energy balance

58 Pharmacological profiling an abundantly expressed schistosome serotonergic GPCR identifies nuciferine as a potent antagonist

59 A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists: Further link between metabolism and psychopathology: Special Section on “Translational and Neuroscience Studies in Affective Disorders”. Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders.

60 A functional agonist of insect olfactory receptors: Behavior, physiology and structure

61 Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018).

62 Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model

63 John Milton's Samson agonistes: Deathly selfhood

64 The AMPA receptor binding site: focus on agonists and competitive antagonists.

65 Patent evaluation: Isatine AMPA antagonists

66 Isatine AMPA antagonists

67 Badminton players show a lower coactivation and higher beta band intermuscular interactions of ankle antagonist muscles during isokinetic exercise.

68 Discrete-Time Fractional Order Integral Sliding Mode Control of an Antagonistic Actuator Driven by Pneumatic Artificial Muscles

69 Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.

70 Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague

71 Evaluation of airway function and inflammation after theophylline controlled release tablet combined with β2 receptor agonist treatment of bronchial asthma

72 Beneficial effects of rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, in a mouse allergic asthma model is not associated with the recruitment or generation of Foxp3-expressing CD4 regulatory T cells.

73 On-chip ion pair-based dispersive liquid-liquid extraction for quantitative determination of histamine H2 receptor antagonist drugs in human urine

74 Comparison of recombinant and urinary follicle-stimulating hormones over 2000 gonadotropin-releasing hormone antagonist cycles: a retrospective study

75 Effect of constant light and immobilization stress on rat submandibular saliva secretory response induced by cholinergic and peptidergic agonists

76 Author-characters and authorial public image: The elderly protagonists in philip roth and nicole krauss

77 Efficacy and hypoglycemic risk of sitagliptin in obese/overweight patients with type 2 diabetes compared with GLP-1 receptor agonists: A meta-analysis.

78 β-Fluorofentanyls Are pH-Sensitive Mu Opioid Receptor Agonists.

79 The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs

80 An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.

81 Endocrine effects of the novel ghrelin receptor inverse agonist PF-5190457: Results from a placebo-controlled human laboratory alcohol co-administration study in heavy drinkers.

82 Anti-Tumor Potential of a 5-HT3 Receptor Antagonist as a Novel Autophagy Inducer in Lung Cancer: A Retrospective Clinical Study with In Vitro Confirmation.

83 Effects of GABA-B agonist baclofen on esophageal motility: Studies using high-resolution manometry.

84 Alignment independent 3D-QSAR studies and molecular dynamics simulations for the identification of potent and selective S1P receptor agonists.

85 QSAR models on H receptor antagonists associated with inflammation and anaphylaxis.

86 Resolution of new daily persistent headache by a tumor necrosis factor alpha antagonist, Venlafaxine.

87 New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients.

88 Biological control of chestnut canker, caused by Cryphonectria parasitica, by antagonistic organisms and hypovirulent isolates

89 Pseudolaric acid analogs as a new class of peroxisome proliferator-activated receptor agonists.

90 Comparative docking to distinct G protein-coupled receptor conformations exclusively yields ligands with agonist efficacy.

91 Hypolipidemic effect of novel 2,5-bis(4-hydroxybenzylidenamino)-1,3,4-thiadiazole as potential peroxisome proliferation-activated receptor-α agonist in acute hyperlipidemic rat model

92 Down-regulation of vimentin by triorganotin isothiocyanates - nuclear retinoid X receptor agonists: A proteomic approach.

93 Educación informal. Configuración y valores de los protagonistas infantiles

94 A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.

95 Bacterial antagonists and hexanal-induced systemic resistance of mango fruits against lasiodiplodia theobromae causing stem-end rot

96 Dişi Köpek Ve Kedilerde Üremenin Kontrolünde GNRH Agonistleri

97 In vitro study on the agonistic and antagonistic activities of bisphenol-S and other bisphenol-A congeners and derivatives via nuclear receptors.

98 PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium.

99 Differences in receipt of opioid agonist treatment and time to enter treatment for opioid use disorder among specialty addiction programs in the United States, 2014-17.

100 Honokiol: a non-adipogenic PPARγ agonist from nature.

101 Atypical feminized male’s agonistic behavior relative to males and females of Nile tilapia (Oreochromis niloticus L.)

Keyword Connections

Journals

Research Groups

Bibliographies